GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » EV-to-Revenue

Valneva SE (Valneva SE) EV-to-Revenue : 3.63 (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Valneva SE EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Valneva SE's enterprise value is $601.5 Mil. Valneva SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $165.8 Mil. Therefore, Valneva SE's EV-to-Revenue for today is 3.63.

The historical rank and industry rank for Valneva SE's EV-to-Revenue or its related term are showing as below:

INRLF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.86   Med: 3.27   Max: 45.61
Current: 3.65

During the past 13 years, the highest EV-to-Revenue of Valneva SE was 45.61. The lowest was 0.86. And the median was 3.27.

INRLF's EV-to-Revenue is ranked better than
68.82% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs INRLF: 3.65

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), Valneva SE's stock price is $3.48. Valneva SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.20. Therefore, Valneva SE's PS Ratio for today is 2.91.


Valneva SE EV-to-Revenue Historical Data

The historical data trend for Valneva SE's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE EV-to-Revenue Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 5.48 6.73 2.01 4.80

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 1.52 2.55 3.55 4.80

Competitive Comparison of Valneva SE's EV-to-Revenue

For the Biotechnology subindustry, Valneva SE's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Valneva SE's EV-to-Revenue falls into.



Valneva SE EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Valneva SE's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=601.488/165.789
=3.63

Valneva SE's current Enterprise Value is $601.5 Mil.
Valneva SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $165.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE  (OTCPK:INRLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Valneva SE's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.48/1.195
=2.91

Valneva SE's share price for today is $3.48.
Valneva SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.20.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Valneva SE's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (Valneva SE) Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.